Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
Pulse Biosciences (PLSE) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. LaViolette brings extensive experience from his roles at Boston Scientific , where he served as Chief Operating Officer and various executive positions over 15 years. He also has significant venture investment experience as Managing Partner at SV Health Investors.
The company is developing its nano-PFA Cardiac Surgical System and nano-PFA 360° Cardiac Catheter, conducting first-in-human feasibility studies in Europe and a pilot program with FDA-cleared nsPFA Percutaneous Electrode Systems in the US. The company will present at the J.P. Morgan Healthcare Conference and the AF Symposium 2025.
Additionally, PLSE granted inducement awards of options to purchase 138,800 shares to eleven new employees, with an exercise price of $18.55 per share and various vesting schedules, including performance-based vesting tied to market capitalization milestones between $1-3 billion.
Pulse Biosciences (PLSE) ha nominato Paul A. LaViolette, attuale Co-Presidente del Consiglio, come Amministratore Delegato. LaViolette porta con sé un'importante esperienza dai suoi ruoli presso Boston Scientific, dove ha ricoperto la carica di Chief Operating Officer e diverse posizioni dirigenziali per oltre 15 anni. Ha anche una significativa esperienza in investimenti di rischio come Managing Partner di SV Health Investors.
L'azienda sta sviluppando il proprio nano-PFA Cardiac Surgical System e il nano-PFA 360° Cardiac Catheter, conducendo studi di fattibilità primi al mondo in Europa e un programma pilota con i sistemi di elettrodi percutanei nsPFA approvati dalla FDA negli Stati Uniti. L'azienda presenterà alla J.P. Morgan Healthcare Conference e all'AF Symposium 2025.
Inoltre, PLSE ha concesso premi di incentivo sotto forma di opzioni per l'acquisto di 138.800 azioni a undici nuovi dipendenti, con un prezzo di esercizio di $18.55 per azione e vari programmi di maturazione, inclusi vincoli basati sulle prestazioni legati a traguardi di capitalizzazione di mercato tra $1-3 miliardi.
Pulse Biosciences (PLSE) ha nombrado a Paul A. LaViolette, actual Co-Presidente de la Junta, como Director Ejecutivo. LaViolette aporta una amplia experiencia de sus roles en Boston Scientific, donde se desempeñó como Director de Operaciones y ocupó diversas posiciones ejecutivas durante más de 15 años. También tiene una importante experiencia en inversiones de riesgo como Socio Gerente en SV Health Investors.
La empresa está desarrollando su sistema quirúrgico cardíaco nano-PFA y el catéter cardíaco nano-PFA 360°, llevando a cabo estudios de viabilidad en humanos en Europa y un programa piloto con sistemas de electrodos percutáneos nsPFA aprobados por la FDA en los EE. UU. La empresa presentará en la Conferencia de Salud J.P. Morgan y en el Simposio AF 2025.
Además, PLSE otorgó premios de incentivos de opciones para comprar 138,800 acciones a once nuevos empleados, con un precio de ejercicio de $18.55 por acción y varios cronogramas de adquisición, incluidos aquellos basados en el desempeño vinculados a hitos de capitalización de mercado entre $1-3 mil millones.
펄스 바이오사이언스 (PLSE)는 현재 이사회의 공동 의장인 Paul A. LaViolette를 최고경영자(CEO)로 임명했습니다. LaViolette는 보스턴 사이언티픽에서 COO 및 다양한 경영직을 맡으며 15년 이상의 폭넓은 경험을 쌓았습니다. 그는 또한 SV Health Investors의 관리 파트너로서 중요한 벤처 투자 경험을 가지고 있습니다.
회사는 나노-PFA 심장 수술 시스템과 나노-PFA 360° 심장 카테터를 개발하고 있으며, 유럽에서 첫 인간 적용 가능성 연구를 진행 중이며, 미국에서는 FDA 승인을 받은 nsPFA 경피적 전극 시스템으로 파일럿 프로그램을 진행하고 있습니다. 회사는 J.P. Morgan 헬스케어 컨퍼런스와 AF 심포지엄 2025에 발표할 예정입니다.
또한, PLSE는 11명의 신규 직원에게 138,800주를 구매할 수 있는 선택권을 부여했으며, 주당 행사 가격은 $18.55이고, 시장 가치 기준의 성과 기반 형식이 포함된 다양한 매입 일정이 있습니다.
Pulse Biosciences (PLSE) a nommé Paul A. LaViolette, actuel Co-Président du Conseil, en tant que Directeur Général. LaViolette apporte une vaste expérience de ses fonctions chez Boston Scientific, où il a occupé le poste de Directeur des Opérations et divers postes exécutifs pendant plus de 15 ans. Il a également une expérience significative en investissement de capital-risque en tant que Partenaire Gestionnaire chez SV Health Investors.
L'entreprise développe son système chirurgical cardiaque nano-PFA et son cathéter cardiaque nano-PFA 360°, menant des études de faisabilité chez l'homme en Europe et un programme pilote avec des systèmes d'électrodes par voie percutanée nsPFA approuvés par la FDA aux États-Unis. L'entreprise se présentera à la Conférence J.P. Morgan Healthcare et au Symposium AF 2025.
De plus, PLSE a accordé des primes d'incitation sous forme d'options d'achat de 138 800 actions à onze nouveaux employés, avec un prix d'exercice de 18,55 $ par action et divers calendriers d'acquisition, y compris des acquisitions basées sur la performance liées à des jalons de capitalisation boursière entre 1 et 3 milliards de dollars.
Pulse Biosciences (PLSE) hat Paul A. LaViolette, derzeit Co-Vorsitzender des Vorstands, zum Chief Executive Officer ernannt. LaViolette bringt umfangreiche Erfahrungen aus seiner Tätigkeit bei Boston Scientific mit, wo er 15 Jahre lang als Chief Operating Officer und in verschiedenen leitenden Positionen tätig war. Er verfügt außerdem über umfassende Erfahrung in der Wagniskapitalbeschaffung als Managing Partner bei SV Health Investors.
Das Unternehmen entwickelt sein nano-PFA Herzchirurgisches System und den nano-PFA 360° Herzkatheter und führt in Europa Machbarkeitsstudien mit Menschen durch sowie ein Pilotprogramm mit von der FDA genehmigten nsPFA perkutanen Elektroden-Systemen in den USA. Das Unternehmen wird auf der J.P. Morgan Healthcare Conference und dem AF Symposium 2025 präsentieren.
Zusätzlich hat PLSE Induktionsvergütungen in Form von Optionen zur Kaufwahl von 138.800 Aktien an elf neue Mitarbeiter gewährt, mit einem Ausübungspreis von 18,55 $ pro Aktie und verschiedenen Vesting-Plänen, einschließlich leistungsabhängiger Vesting-Kriterien, die an Marktkapitalisierungsmeilensteine zwischen 1-3 Milliarden $ gebunden sind.
- Appointment of experienced executive with significant medical technology industry background
- Ongoing development of nano-PFA technology with active clinical studies in Europe
- FDA clearance already obtained for nsPFA Percutaneous Electrode Systems
- Stock option grants may lead to potential shareholder dilution
Current Co-Chairman of the Board will now also serve as Chief Executive Officer
"We are thrilled to have Paul assume the role of Chief Executive Officer," said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. "Having worked very closely with Paul, we have established a strong working relationship and have realized our visions for the future of Pulse closely align. His impressive track record and network in the medical technology space spans decades and is a testament to his ability to lead organizations and create value. Particularly, Paul’s experience scaling global franchises across multiple clinical specialties and driving the adoption of innovative technologies will now be an even greater asset for Pulse moving forward.”
Paul LaViolette has significant experience as a large-scale operator at global healthcare corporations as well as a leader to a diverse group of innovative medical technology startups as a venture investor and board member. As a Managing Partner at SV Health Investors, Paul invested in numerous portfolio companies and remains active on the Board of Directors of certain SV Health Investors portfolio companies. Before his investing career, he served in various executive capacities at Boston Scientific Corporation for 15 years, including as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. Prior to Boston Scientific, he also served as President, Cardiology, for CR Bard and various marketing roles at Kendall (Medtronic).
Mr. LaViolette is currently a director for Edwards Lifesciences and Chairman of the Innovation Advisory Board at Mass General Brigham. Mr. LaViolette received his bachelor’s degree in psychology from
"I believe nano-PFA is a remarkable advance in medical technology and will make a profound impact on healthcare for the benefit of countless patients and providers," said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. "The established team, innovative technologies and portfolio of therapies under development attracted me to Pulse. Having now worked with Bob and the team, I am thrilled to take on this role and cannot wait to contribute to the Company’s continued success.”
Pulse Biosciences is continuing the development of its nano-PFA Cardiac Surgical System and nano-PFA 360° Cardiac Catheter through first-in-human feasibility studies in
Inducement Grants
Additionally, the Company announced today the grant of inducement awards of options to purchase a collective total of up to 138,800 shares of common stock to eleven other new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. These inducement awards were granted on January 7, 2025. The options have a ten (10) year term and an exercise price of
The options awarded under the Inducement Plan will be subject to the terms of a stock option agreement to be executed by each grant recipient. The Company is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250110915533/en/
Investors:
Pulse Biosciences, Inc.
Paul LaViolette, Co-Chairman and CEO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
What is Paul LaViolette's background before joining Pulse Biosciences (PLSE) as CEO?
What clinical trials is PLSE currently conducting with its nano-PFA technology?
What are the details of PLSE's January 2025 stock option grants?
Where will PLSE present its nano-PFA technology in January 2025?
